Cargando…
“It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing
BACKGROUND: In South-Eastern Norway, genetic testing for BRCA1 and BRCA2 is offered to breast cancer patients by their treating surgeon or oncologist. Genetic counselling from a geneticist or a genetic counsellor is offered only to those who test positive for a pathogenic variant or have a family hi...
Autores principales: | Strømsvik, Nina, Olsson, Pernilla, Gravdehaug, Berit, Lurås, Hilde, Schlichting, Ellen, Jørgensen, Kjersti, Wangensteen, Teresia, Vamre, Tone, Heramb, Cecilie, Mæhle, Lovise, Grindedal, Eli Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818154/ https://www.ncbi.nlm.nih.gov/pubmed/35123550 http://dx.doi.org/10.1186/s13053-022-00212-6 |
Ejemplares similares
-
Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway
por: Grindedal, Eli Marie, et al.
Publicado: (2020) -
BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway
por: Heramb, Cecilie, et al.
Publicado: (2018) -
BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
por: Norum, Jan, et al.
Publicado: (2018) -
Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers
por: Grindedal, Eli Marie, et al.
Publicado: (2017) -
The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry
por: Grindedal, Eli Marie, et al.
Publicado: (2014)